We appreciate you visiting EmpowHER, but you must be logged in to view this page. If you are already a member, please log in here. If you are not a member yet, please fill out the form to start your free membership today.
Dasatinib (Sprycel) and nilotinib (Tasigna) are now considered first line treatments for CML.Imatinib (Gleevec) remains a first line treatment. These options can be very confusing for patients. EmpowHER member and partner Andrew Schorr, of PatientPower.info, conducted an in-depth interview about this topic with Dr. Jorge Cortes, noted CML expert from M. D. Anderson Cancer Center.
You can find the interview here:
http://www.patientpower.info/p2tv.asp?video=12339147&autoplay=1
Comment Reply
Dasatinib (Sprycel) and nilotinib (Tasigna) are now considered first line treatments for CML.Imatinib (Gleevec) remains a first line treatment. These options can be very confusing for patients. EmpowHER member and partner Andrew Schorr, of PatientPower.info, conducted an in-depth interview about this topic with Dr. Jorge Cortes, noted CML expert from M. D. Anderson Cancer Center.
September 16, 2010 - 6:49pmYou can find the interview here:
http://www.patientpower.info/p2tv.asp?video=12339147&autoplay=1
This Comment
Reply